Things happen ever faster on the second half of the chessboard. No sooner had the ink dried on our predictions for 2015, and Dr Eric Topol told the story of the first patient to call him with a smartphone diagnosis than Alivecor announced that they now have CE certification for their AF-diagnosing app.
Mind you, whilst Dr Topol might welcome this, it seems that others are still on a different chessboard: under the heading “Doctors fear that new health tech is turning UK into a nation of “worried well””, a recent survey of UK doctors showed that “Seven out of ten (76%) GPs said they had noticed a marked increase in number of patients “self-diagnosing” from the internet over the past twelve months” suggesting, in the words of 1066 & all that, that technology is a Bad Thing. What, this reviewer wonders, will be the reaction to (more…)
This event was held on April 28th-30th in Victoria in London. It was organised by Pharma IQ and clearly had a strong pharma focus (including the charge which at £1995 for industry attendees clearly discriminated in favour of those with big-pharma sized budgets). It was also held just a few days after the significantly lower-priced Royal Society of Medicine event, and in the middle of a London Tube strike, all of which doubtless contributed to the relatively modest attendance (26 paid). I am most grateful to the organisers for kindly inviting me as one of speaker Alex Wyke’s guests.
As mentioned in an earlier post, there was a similarity with the RSM agenda, so I won’t repeat comments made by the same speaker before. The first up was the 3G Doctor, David Doherty, who gave another of his excellent presentations, although the sound engineer sadly made some of it inaudible. After a review of how we had got to where we are, he suggested that the Internet is about to become a device-dominated network. He drew a parallel between (more…)
We have written extensively in recent months about how technology is changing the way patients are using doctors, yet some, notably the RCGP in their vision of GP practice in 2022, seem unprepared, or unwilling to accept this. Well if more evidence of the coming change were needed, AliveCor’s announcement that it now has FDA approval for sales of its (iOS & Android) smartphone-enabled heart monitor direct to the public will perhaps provide some.
In particular, the announcement includes a service – available in the US only at present – called AliveInsights, that will (more…)
Editor Charles on what to watch for in 2014
As we have covered previously (and here), there’s no shortage of forecasts that the mHealth market will continue to grow faster, or of penetrating comments like that that won Research2guidance a What in the Blue Blazes award that smartphone user penetration will be the main driver for the mobile health (mHealth) uptake. mHealth apps continue to proliferate – there’s even shortly to be a Pebble apps store. There are a few straws in the wind that not is all well though – for example, as we covered recently, Happtique ceased, at least temporarily, its apps approval process, citing security concerns. Elsewhere Fierce Mobile described serious data privacy issues with the iPharmacy app, and the ICO recently produced security guidelines for app developers in the UK. The EU is also strengthening data privacy, moving from individual country directives to a pan-EU regulation. This leads us to our first prediction (more…)